Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

Inclusion Criteria: Have a primary diagnosis of B cell non-Hodgkin lymphoma \- Histologically confirmed: Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B Cell Lymphoma (PMBCL), Transformation Follicular Lymphoma (TFL), High grade B-cell Lymphoma (HGBCL), Mantle cell Lymphoma (MANT), Burkitt Lymphoma (BURK), Lymphoblastic Lymphoma * Chemotherapy-refractory disease, defined as one of more of the following No response to last line of therapy OR Refractory post-autologous stem cell transplant (ASCT) * Individuals must have received adequate prior therapy including at a minimum: anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20-negative and an anthracycline containing chemotherapy regimen for individual with transformed FL must have chemorefractory disease after transformation to DLBCL. * No active infection of HIV, HTLV and Syphilis * Adequate renal function * Adequate hepatic function * Adequate cardiac function * Adequate venous access for apheresis, and no other contraindications for leukapheresis * Voluntary informed consent is given. Exclusion Criteria: A subject will not be eligible for inclusion in this study if any of the following criteria apply: * Received allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) * Body weight less than 30 kg * Pregnant or lactating women. * Uncontrolled active infection. * History of hepatitis B or hepatitis C infection. * Previously treatment with any gene therapy products or cell therapy product in past 28 days. * HIV infection. * Lymphoma with central nervous system (CNS) involvement * Have autoimmune disorders * Have active infection or inflammatory disorders * Prescreening test results in expansion rate less than 5 folds * An allergy to gentamycin and/or streptomycin